PetVivo Holdings, Inc. announced that the Company has released the results of a clinical study conducted by Inotiv, Inc., a world-renowned independent clinical research organization, which examined the safety of intra-articular injections of collagen-elastin hydrogel microparticulates (i.e. Spryng? with OsteoCushion? Technology) into the joints of cats.

The data provided demonstrated the excellent safety profile of Spryng when injected IA into 40 joints (10 each, shoulder, hip, elbow, stifle) across 10 individual cats. Use of Spryng was similar to a benign control (saline) in regard to incidences of lameness, joint swelling, or pain after IA injection, and post-injection outcomes were most often no different than pre-injection baseline measures.